EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics

Yezhou Liu, Yizhen Lyu, Yamei Liu, Jiaheng Zhang, Zhaojie Song, Kangyu Chen, Zhixin Jiang, Hong Yan, Tao Chen, Chao Li

Kidney International · 2026-07 · 110 (1) · 178-189

DOI: 10.1016/j.kint.2026.02.032 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Kidney International, 2026-07. Verfasst von Yezhou Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Antihypertensive Agents, Blood Pressure, Glomerular Filtration Rate, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Despite established cardiovascular benefits, the effects of intensive blood pressure (BP) lowering and specific agents on kidney function remain debated. Here, we assessed these effects using a validated hierarchical composite kidney endpoint (HCE) that prioritizes clinical severity. METHODS: This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m2, eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties. RESULTS: A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58-0.64]) and ACCORD-BP (WO, 0.64 [0.59-0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84-0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25-1.33]) and amlodipine (WO, 1.38 [1.34-1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93-0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses. CONCLUSIONS: Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation. TRIAL REGISTRATION: Registered at Clinicaltrials.gov with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsBlood PressureGlomerular Filtration RateHypertensionKidneyRenal InsufficiencyAgedFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

eGFR slopehierarchical composite kidney end pointhypertensionintensive blood pressure targetskidney safetywin odds

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
  • Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
  • Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China; Department of Clinical Sciences, Liverpool School of Tropical Medicine,…
  • Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaot…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., Lyu, Y., Liu, Y., Zhang, J., Song, Z., Chen, K., Jiang, Z., Yan, H., Chen, T., & Li, C. (2026). Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics. Kidney International, 110(1), 178-189. https://doi.org/10.1016/j.kint.2026.02.032

Vancouver

Liu Y, Lyu Y, Liu Y, Zhang J, Song Z, Chen K, et al. Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics. Kidney International. 2026;110(1):178-189. doi:10.1016/j.kint.2026.02.032

BibTeX
@article{Liu2026,
  author = {Liu, Yezhou and Lyu, Yizhen and Liu, Yamei and Zhang, Jiaheng and Song, Zhaojie and Chen, Kangyu and Jiang, Zhixin and Yan, Hong and Chen, Tao and Li, Chao},
  title = {Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {1},
  pages = {178--189},
  doi = {10.1016/j.kint.2026.02.032}
}
Kostenlos starten →